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Background: The relationship between the pathogenic amyloid β-peptide species Aβ1–42 and tau pathology has
been well studied and suggests that Aβ1–42 can accelerate tau pathology in vitro and in vivo. The manners if any
in which Aβ1–40 interacts with tau remains poorly understood. In order to answer this question, we used cell-based
system, transgenic fly and transgenic mice as models to study the interaction between Aβ1–42 and Aβ1–40.
Results: In our established cellular model, live cell imaging (using confocal microscopy) combined with biochemical
data showed that exposure to Aβ1–42 induced cleavage, phosphorylation and aggregation of wild-type/full length tau
while exposure to Aβ1–40 didn’t. Functional studies with Aβ1–40 were carried out in tau-GFP transgenic flies and
showed that Aβ1–42, as previously reported, disrupted cytoskeletal structure while Aβ1–40 had no effect at same
dose. To further explore how Aβ1–40 affects tau pathology in vivo, P301S mice (tau transgenic mice) were injected
intracerebrally with either Aβ1–42 or Aβ1–40. We found that treatment with Aβ1–42 induced tau phosphorylation,
cleavage and aggregation of tau in P301S mice. By contrast, Aβ1–40 injection didn’t alter total tau, phospho-tau
(recognized by PHF-1) or cleavage of tau, but interestingly, phosphorylation at Ser262 was shown to be significantly
decreased after direct inject of Aβ1–40 into the entorhinal cortex of P301S mice.
Conclusions: These results demonstrate that Aβ1–40 plays different role in tau pathogenesis compared to
Aβ1–42. Aβ1–40 may have a protective role in tau pathogenesis by reducing phosphorylation at Ser262, which has
been shown to be neurotoxic.
Keywords: Aβ1–42, Aβ1–40, tau, Alzheimer’s disease, Aggregation, Phosphorylation, CleavageBackground
Two major hallmarks of Alzheimer’s disease (AD) are
the accumulation of the amyloid-β peptides (Aβ) into
extracellular plaques and the formation of intracellular
neurofibrillary tangles (NFTs) composed mainly of the
protein tau. Aβ exists as two main species, Aβ1-42 and
Aβ1-40, and the unique relationship between each of
these peptides on tau pathology has not been adequately
addressed. It is generally believed that Aβ accrual in
brain is an early event in the pathogenesis of AD, prece-
ding significant tau pathology. Intracerebral administra-
tion of synthetic Aβ1-42 fibrils into P301L mice (mutant
human tau transgenic mice) induced tau hyperphospho-
rylation and local neurofibrillary tangles [1,2]. Natural* Correspondence: xih2006@med.cornell.edu; stp2015@med.cornell.edu
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unless otherwise stated.Aβ oligomers, specifically dimers, isolated from a human
AD brain, were sufficient to induce tau hyperphosphory-
lation at AD-relevant epitopes as well as microtubule
disruption and neuritic degeneration [3]. These experi-
ments were done either with Aβ1-42 or a mixture of
Aβ1-42 and Aβ1-40; however, increasing evidence sug-
gests that Aβ1-40 and Aβ1-42 differentially contribute
to the disease process [4]. BRI-Aβ40 mice, a model that
exclusively expresses high levels of Aβ1-40, do not de-
velop amyloid pathology in the form of diffuse or neur-
itic Aβ plaque. BRI-Aβ42 mice, on the other hand, a
model that exclusively expresses Aβ1-42, and at levels
10-fold lower than BRI-Aβ40 mice express Aβ1-40, de-
veloped amyloid deposits in the cerebellum as early as
3 months of age [4]. By crossing BRI-Aβ40 or BRI-Aβ42
mice with Tg2576 (APPswe, K670N +M671L) mice, it
has been shown that Aβ1-42 and Aβ1-40 have opposing
effects on amyloid deposition; Aβ42 promotes amyloidThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bition of angiotensin-converting enzyme (ACE), which
converts Aβ42 to Aβ40, enhanced brain amyloid depos-
ition in Tg2576 mice [6]. Emerging evidence therefore
indicates a protective role for Aβ1-40 in AD pathogen-
esis. One such theory suggests that Aβ1-40 may act to
stabilize Aβ1-42 monomers by competing for binding
sites on pre-existing Aβ1-42 aggregates [7] and thereby
inhibiting further aggregation of Aβ1-42 [8].
Aβ1-42 has also been shown to increase the phospho-
rylation and aggregation of tau both in vivo [1] and
in vitro [3,9]; however, the interaction between Aβ1-40
and tau has not, to our knowledge, been explored. In-
creasing experimental evidence on differential (in some
cases opposite) roles that Aβ1-40 and Aβ1-42 may play
in amyloid deposition raises the question of whether
Aβ1-40 alters tau phosphorylation and/or aggregation in
the same manner as Aβ1-42. Here, we address this issue
by using: 1) a cell-based model to study the effects of
Aβ1-42 and Aβ1-40 on tau aggregation using live cell
imaging; 2) a transgenic Drosophila model to examine
the direct impact on cytoskeleton structure caused by
Aβ1-42 and Aβ1-40; 3) a tau transgenic mouse model to
compare the effects of Aβ1-42 and Aβ1-40 on tau pa-
thogenesis. Here we show that Aβ1-42 induces tau phos-
phorylation, aggregation and cleavage whereas Aβ1-40
does not.
Results
Full-length tau aggregates quickly in SHSY5Y and C17.2
cells, but not in N2a cells
To explore the capability of wild-type full-length tau
(2N4R, Tau441) to aggregate in living cells, SHSY5Y,
C17.2 and N2a cells were plated on an ibidi u-Slide 8
well chamber and transiently transfected with Tau441-
YFP (2N4R—longest form of human tau) using lipofec-
tamine 2000. Twenty four hours later, live cells images
were taken using a confocal microscope (see Methods).
Darkfield and phase contrast views of cells were shown
side to side. Darkfield images showed better fluorescence
signal (especially for intracellular aggregates) and phase
contrast provided images for the whole cell. As shown in
Figure 1A, after 24 h we observed the aggregation of full
length tau in the vesicles of C17.2 cells and SHSY5Y cells
(Red arrow in Figure 1B) but not in N2a cells, suggesting
cellular specificity for the aggregation of tau. This is the
first study to show that wild-type full-length tau can form
aggregates without the addition of exogenous recombin-
ant tau fibrils. By quantifying the fluorescent intensity of
YFP linked to Tau441, we calculated the transfection effi-
ciency in N2a cells to be approximately 85% compared to
35% for C17.2 and 5% for SHSY5Y cells.
To examine the aggregation of Tau441 in N2a cells
over time, live cell images were taken at 24 h, 48 h and72 h after transfection. Tau aggregates were seen in N2a
cells 72 h after transfection (Figure 1D), but not in YFP
expressing cells, indicating that the aggregates seen in
tau-YFP transfected N2a cells were not YFP-dependent,
but specific for tau. Thioflavin-S (ThS) was used to deter-
mine if tau aggregates were in β-pleated sheets structure
as seen in tau transgenic mice and human AD brain sec-
tions. Seventy two hours after transfection with Tau441-
YFP, N2a cells were fixed and stained with ThS. As shown
in Figure 1E, ThS staining completely overlapped with the
large tau aggregates highlighted with YFP, but not with dif-
fusible tau in cytoplasm.
Aβ1-42 increases the level of insoluble tau while Aβ1-40
has no effect
In vivo, Aβ1-42 is more prone to forming amyloid
plaque than Aβ1-40. In fact, Aβ1-40 has been shown to
have a protective effect by reducing the fibrilization of
Aβ1-42 [5]. Using the cell-based model we established
above, we first determined the respective influence of
Aβ1-40 and Aβ1-42 on tau insolubility. N2a cells were
transfected with Tau441-YFP in the presence of 200 nM
soluble Aβ1-40 or Aβ1-42. Twenty four hours after
transfection, live cell images were taken using confocal
microscopy and there was no difference in the total
fluorescence intensity between the groups (Figure 2A).
To assess the effects of Aβ on tau insolubility, cells were
fixed with 4% PFA containing 1% Triton-X100 for 15 min
to remove soluble tau from the cells. Images shown in
Figure 2B, where the fluorescent signal represents insol-
uble tau, indicate that there was much more insoluble
full-length tau in the presence of Aβ1-42 when compared
to Aβ1-40 and non-treated cells. Quantification of the
fluorescence intensity in these images was done using
Image J (Figure 2C). Cytotoxicity was found in Aβ1-42
treated N2a cells at 72 hr but not in Aβ1-40 treated cells
(data not shown).
Aβ1-42 induces cleavage, phosphorylation and
aggregation of tau while Aβ1-40 does not
To understand the underlying mechanisms that contribute
to the unique roles of Aβ1-42 and Aβ1-40 on tau path-
ology, N2a stable cell line that overexpresses Tau441-YFP
was established. Twenty four hours after treatment with
either Aβ1-42 or Aβ1-40, the cells were homogenized on
ice in 1% Triton-PBS buffer, followed by 1% SDS-PBS buf-
fer. Western blots analysis of Triton and SDS extract using
anti-tau antibodies showed that Aβ1-42 treatment resulted
in increased phosphorylation at Ser262, as recognized by
the pS262 antibody, in both Triton and SDS soluble frac-
tions as compared with N2a cells that did not receive Aβ
treatment (Figure 3A and C). A slight decrease in the
pS262 signal was observed in the SDS fraction from Aβ1-
40 treated cells. Phosphorylation at Ser262 strongly reduces
Figure 1 Expression and aggregation of Tau441-YFP in three different cell types. A) SHSY5Y, C17.2 and N2a cells were transfected with
Tau441-YFP and live cell images were taken at 24 h with a confocal microscope. Darkfield images showed better fluorescence signal and phase
contrast provided images for the whole cell. B) Aggregates formed in SHSY5Y and C17.2 cells (red arrow). C) Quantification of transfection
efficiency was done with Image J. D) Time course of Tau441-YFP expression and aggregation in N2a cells. Aggregates appeared at 72 h after
transfection while no aggregates formed in YFP transfected cells, which suggested that those aggregates were tau specific. E) 72 h after
transfection, cells were fixed with 4% PFA and stained with thioflavin-S (ThS). Only a small population of cells showed ThS-positive aggregates
(red arrow). Cells (green arrow) with diffusely distributed tau were ThS negative even though a high level of Tau441-YFP was expressed in those
cells. This further confirmed that the ThS signal was not a false signal due to the leakage of YFP. Magnification: 63x. Scale bar: 10 μm.
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be a key phosphorylation site implicated in the loss of
function of tau in cytoskeleton stabilization [10]. Ser396/
Ser404 is important phosphorylation site that is recog-
nized by the PHF-1 antibody. In Aβ1-42 treated cells we
also observed a 3-fold increase in total tau and phos-
phorylation at the PHF-1 epitope (Ser396/Ser404) in the
SDS fraction, but we observed no change in Aβ1-40
treated cells (Figure 3B and D). We also observed an
increase in Tau421 (cleavage of tau at Asp421) in the
Triton fraction after Aβ1-42 treatment as visualized
with the tau-C3 antibody (Figure 3A and B). No tau-
C3 signal was detected in the SDS fraction. Our data
are consistent with previous studies on the accelerating
effect of Aβ1-42 on tau pathology. To our knowledge,this is the first study to show that Aβ1-40 has no effect
on tau phosphorylation, cleavage and aggregation.Activation of GSK3β and caspase-3 by Aβ1-42 but not by
Aβ1-40
GSK3β phosphorylates tau at many sites including Ser262,
Ser396 and Ser404. To understand the underlying mechan-
ism responsible for the differences in tau phosphorylation
induced by Aβ1-42 and Aβ1-40 treatments, total GSK3β
and phosphorylated-GSK3β (p-GSK3β) levels were exam-
ined by western blot. Phosphorylation of GSK3β at Tyr216
increases the activity of GSK3β, which leads to more tau
phosphorylation. As shown in Figure 3E, Aβ1-42 treat-
ment increased p-GSK3β (Y216) without changing the
Figure 2 Aβ1-42 induces intracellular full length tau (Tau441-YFP) aggregation in N2a cells. A) N2a cells were transfected with Tau441-YFP
and treated with 200nM Aβ1-40 or Aβ1-42. 24 h later, cells were imaged directly under a confocal microscope. There was no difference in the
expression of tau between the groups. B) Cells were extracted with 1% Triton during fixation, which left only insoluble tau in the cells. As shown
in Figure B, Aβ1-42 treatment increased the level of insoluble full-length tau, but Aβ1-40 did not. C) Quantification of fluorescence intensity was
done with Image J. Magnification: 63x, scale bar: 10 μm. Three individual experiments were done for each condition. *p <0.05.
Hu et al. Molecular Neurodegeneration 2014, 9:52 Page 4 of 11
http://www.molecularneurodegeneration.com/content/9/1/52total GSK3β level. By contrast, Aβ1-40 treatment resulted
in no change in either GSK3β or p-GSK3β.
Aβ1-42 treatment has also been reported to activate
pro-caspase-3 [11] and enhance the cleavage of tau at
Asp421, which results in accelerated aggregation. Consis-
tent with these results, we also found increased Tau421 in
Aβ1-42 treated cells. Western blots with an anti-active
caspase-3 antibody revealed higher levels of active
caspase-3 following Aβ1-42 treatment but not following
Aβ1-40 treatment (Figure 3E and F).
Aβ1-42, but not Aβ1-40, interferes with cytoskeleton
formation in tau transgenic flies
Tau plays an important role in microtubule stabilization
and organization. Changes in the cleavage, phosphorylation
or aggregation of tau may directly lead to the disruption of
microtubules architecture. To study the functional effects
of Aβ on tau, we used a transgenic Drosophila model that
expresses fluorescence GFP labeled tau (TauGFP) in sub-
perineural glia cell. TauGFP labeled microtubule fibers are
visible throughout the cytoplasm, emerging from the
microtubule organizing center (MTOC) adjacent to the
nucleus and extending to the cell cortex (Figure 4). SolubleAβ1-40 or Aβ1-42 (100pM or 10nM) was microinjected
into the body cavity of late embryo (AEL-21-22 hr). Four
days later (3rd instar larvae), the central nerve cord was
dissected out, mounted in PBS and imaged directly with a
confocal microscope [12]. The microtubule cytoskeleton
was easily visualized under confocal microscopy which
allows fluorescence allowing us to measure changes of
microtubule architecture as a result of the Aβ treatment.
At 100pM, the microtubule organization of subperineural
glia cell injected with Aβ1-42 was destabilized and clus-
tered, while the microtubule architecture was normal
in Aβ1-40 injected flies (Figure 4). When we increased
the concentration of Aβ to 10nM, a compromised cyto-
skeleton was observed in both Aβ1-42 and Aβ1-40
injected flies.
Aβ1-42 increases phosphorylated and insoluble tau, when
compared with Aβ1-40, in the entorhinal cortex of P301S
mice
To further examine the effect of Aβ on tau pathology
in vivo, we performed intracerebral injections of Aβ into
P301S mice (tau transgenic mouse model) at 8-months
of age. At 8-months P301S mice have already developed
Figure 3 Aβ1-42 promotes phosphorylation, cleavage and aggregation of tau by increasing GSK3β activity and by activating
pro-caspase3. Sequential extraction was performed on Tau441-YFP-transfected cells treated with transfection reagent alone (control), 200 nM
Aβ1-40 or Aβ1-42 for 24 h. Triton fraction was obtained by extracting intracellular tau with 1% Triton. Triton-insoluble fraction was then solubilized
with 1% SDS to get SDS fraction. A) Triton fraction was electrophoresed and immunoblotted for total tau (HT7), p-tau(Ser396/404) (PHF-1), p-tau
(Thr262) (pS262), Tau421(tau-C3) and β-actin. β-Actin was measured from the same blots to ensure that equal protein was present in every lane.
Aβ1-42 significantly induced p-tau at Thr231 and increased levels of Tau421 were observed in Aβ1-42 treated cells, while no change occurred in
Aβ1-40 treated cells when compared to cells without treatment. B) Quantification of western blots in (A). C) Representative images of western
blots for SDS fraction with HT7, PHF-1 and pS262. All 3 forms of tau increased in Aβ1-42 treated cells. No change in tau level was found in
Aβ1-40 treated cells. There was no detectable signal for tau-C3 in SDS fraction. D) Quantification of western blots in (C). E) Triton fraction was also
blotted with anti-GSK3β antibody, anti-p-GSK3β (Y216) and anti-caspase-3 antibody. Aβ1-42 treatment resulted in an increase in phosphorylation
of GSK3β, which represents higher GSK3β activity. More active caspase-3 was detected in Aβ1-42 treated cells. F) Quantification of western blots
in (E). Histographs show mean +/− standard error, n =3. *p <0.05; ** p <0.01; ***p <0.005.
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targeted the entorhinal cortex as our injection site be-
cause neurons in the entorhinal cortex are more sensi-
tive to Aβ-induced stress [14]. Unilateral injection of
Aβ1-40 (2ug) into the left entorhinal cortex and Aβ1-42
(2ug) into the right entorhinal cortex allowed us to dir-
ectly compare the effects of Aβ1–40 and Aβ1–42 in the
same mouse.
Eighteen days after injection the mice were perfused
with PBS and the brains were isolated, followed by fix-
ation with 4% PFA. As shown in Figure 5A, significant
increases in p-tau (recognized by PHF-1 and pS262) and
Tau 421 (recognized by tau-C3) were observed in S1
fraction from Aβ1-42- injected entorhinal cortex com-
pared to the Aβ1-40 injected entorhinal cortex. Western
blot of P1 fraction from the brain extract (Figure 5C)
showed that, a ≥4 fold increase in HT7, ≥6 fold increasein PHF1 and ≥4 fold increase in pS262 signal in Aβ1–42
treated as compared to Aβ1–40 treated entorhinal cortex.
Immunohistochemistry with AT180, which recognizes
phosphor-Thr231, suggests that injection of Aβ1-42 pro-
motes greater phosphorylation and aggregation of tau
when compared to Aβ1-40 in both the entorhinal cortex
and hippocampus (Figure 6).
Aβ1–42 promotes tau pathology while Aβ1–40 may
inhibit tau pathology
The difference between Aβ1-40 and Aβ1-42-induced re-
lated tau pathology, shown in Figure 5, could be due to
either an accelerating effect by Aβ1-42 or an inhibitory
effect of Aβ1-40. To address this question, two groups
of P301S mice were injected in the entorhinal cortex.
One group was injected with PBS into the left entorhinal
cortex and Aβ1-40 (2ug) into the right entorhinal cortex,
Figure 4 Aβ1-42 disrupts cytoskeleton in transgenic fly at 100pM. Aβ1-40 or Aβ1-42 was diluted in 4% BSA and injected into the body
cavity of late embryo of GFP-tau (bovine Tau) transgenic fly (AEL-21-22 hr). 4 days later, the central nerve cord was dissected out, and mounted
in PBS and imaged directly with a confocal microscope. Stacks of 20–40 0.5 μm confocal sections were generated. The results for each section
were assembled as a stack. At 100pM, damage to the structure of cytoskeleton was observed in Aβ1-42 treated flies but not in flies receiving the
Aβ1-40 treatment. At 10nM, both Aβ1-40 and Aβ1-42 led to disruption of the cytoskeleton.
Figure 5 Higher level of total tau, phospho-tau and cleaved tau in P301S mice receiving an Aβ1-42 injection into the entorhinal cortex
as compared with Aβ1-40 injection. 8 month old P301S mice were injected with Aβ1-40 into the left entorhinal cortex and Aβ1-42 into the
right entorhinal cortex. 18 days after injection, the brain extracts were analyzed by western blot. A) Representative images of western blots of
soluble tau (S1 fraction) detected with anti-tau antibodies and normalized to actin. B) Quantification of western blots in (A). C) Representative
images of western blots of insoluble tau (P1 fraction) detected with anti-tau antibodies. Both S1 brain fraction and P1 brain fraction show a
significant increase in HT7, PHF-1 and pS262 signal in entorhinal cortex injected with Aβ1-42 compared with Aβ1-40 injected entorhinal cortex.
Also more cleaved tau (Tau421) was detected in the S1 fraction from the Aβ1-42 injected brain. D) Quantification of western blots in (C).
Histographs show mean +/− standard error, n =3. *p <0.05; **p <0.01; ***p <0.005.
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Figure 6 Aβ1-42 treatment increases pathological tau recognized by AT180 when compared with Aβ1-40 treatment. Brain sections were
immunostained with AT180, which recognizes p-tau at Thr231. (A) Representative images for pathological tau detected with AT180. (B) Higher
magnification showed significantly increased tau tangles in Aβ1-42 injected entorhinal cortex (C) and hippocampus (B). Magnification: 4x for A;
10x for B and C. Scale bar: 100um.
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torhinal cortex and Aβ1–42 (2ug) into the right entorhi-
nal cortex. Eighteen days after injection, the mice were
sacrificed and the whole hemibrains were dissected and
analyzed by western blot. As shown in Figure 7A, there
were higher levels of p-tau at Ser262, Ser396 and Ser404 in
the Aβ1–42- injected side when compared to the contra-
lateral PBS side (S1 fraction in Figure 7A and P1 fraction
in Figure 7B). There were also higher levels of cleaved
tau and insoluble tau after Aβ1-42 injection. We there-
fore conclude that Aβ1–42 accelerated tau pathology in
P301S mice. For the Aβ1–40 treated group, we didn’t ob-
serve any differences in total tau, p-tau (PHF-1 specific) or
cleaved tau. Interestingly, in the Aβ1-40-injected entorhi-
nal cortex, we observed less phosphorylation at Ser262 in
both S1 and P1 fraction.
Discussion
Our data demonstrates that Aβ1-40 and Aβ1-42 have
distinct effects on tau phosphorylation, aggregation and
cleavage as shown in a variety of in vitro and in vivo
models. Most cellular models previously used to study
tau pathogenesis used a MTBR (microtubule binding do-
mains) ta fragment instead of full-length tau. In recent
years, increasing evidence has revealed that self-aggregation
of tau into filaments is inhibited by the presence of intact
N- and C-termini. The N-terminus is required for the bind-
ing of tau to the plasma membrane while cleavage at
Asp421 (20 amino acids from C-terminus) significantly in-
creases tau aggregation. Therefore, using full-length tau(2N4R, 441 amino acids) may be more relevant for studying
the metabolism of tau, especially tau cleavage. The con-
struct we used in our experiments, Tau441-YFP incorpo-
rates YFP to the C-terminus of tau which doesn’t interfere
with the normal functions of the N-terminus of tau [15].
Tau is a highly soluble protein and is less prone to ag-
gregate in many cell-based models [16]. To our know-
ledge, our study is the first to show that full-length tau
can aggregate in certain cell type, SHSY5Y and C17.2
cells, as early as 24 h after transient transfection and
without the addition of exogenous seeds. In addition, the
rate of tau aggregation was not correlated with the level
of tau expression because no aggregates formed in N2a
cells at 24 h even though our N2a cells expressed a
much higher level of full-length tau. For cells with lower
degradation efficiency, tau aggregation may occur earlier,
consistent with what we found in SHSY5Y and C17.2
cells. Even for cells with high degradation efficiency, con-
tinuous overexpression of tau may eventually overwhelm
degradation ultimately leading to aggregation. Tau aggre-
gates appeared by 72 h in the N2a cells and stained posi-
tively with Thioflavin-S, indicating that overexpression of
tau is another factor that contributes to tau aggregation
and subsequent fibrilization.
Among the many tau phosphorylation sites, Ser262 is
the major site implicated in the abnormal functioning
of tau in the AD brain [10,16]. Our biochemical data,
from treating stably transfected cell lines overexpress-
ing Tau441-YFP with Aβ1-42, indicate increased phos-
phorylation at Ser262 in both Triton and SDS soluble
Figure 7 Aβ1-42 promotes tau phosphorylation, cleavage and aggregation while Aβ1-40 does not. 8 month old P301S mice (1N4R form
with Prion promoter) were injected with saline into the left entorhinal cortex and Aβ1-42 (2ug) into the right entorhinal cortex or saline into the
left entorhinal cortex and Aβ1-40 (2ug) into the right entorhinal cortex. 18 days after injection, the brain extracts were analyzed by western blot.
A) Representative images of western blots of soluble tau (S1 fraction) detected with anti-tau antibodies and normalized to actin. B) Quantification
of western blots in (A). C) Representative images of western blots of insoluble tau (P1 fraction), detected with anti-tau antibodies. D) Quantification of
western blots in (C) Aβ1-42 injection significantly induced tau phosphorylation (PHF-1 and pS262 epitope) in the S1 and P1 brain fractions. 3-fold
increase in Tau421 was found in the soluble fraction (A and B). Significant decrease in pS262 immunoreactivity was observed in S1 fraction from
Aβ1-40 injected brain areas compared to control side. Histographs show mean +/− standard error, n =3. *p <0.05; **p <0.01; ***p <0.005.
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and non-treated cells. Phosphorylation at Ser262 dramati-
cally reduces the ability of tau to bind to microtubules,
which ultimately results in microtubule destabilization.
Microtubule destabilization affects synaptic vesicle trans-
port and may disrupt synaptic function in vivo [17]. In
transgenic Drosophila expressing both human Aβ1-42
and tau, Aβ1-42 specifically increases tau phosphorylation
at Ser262 and enhances tau-induced neurodegeneration
[18]. Co-expression of Aβ1-42 and tau carrying the non-
phosphorylatable Ser262Ala mutation did not cause neu-
rodegeneration, suggesting that the Ser262 phosphorylation
is required for the pathogenic interaction between Aβ1-42
and tau [18]. We found that at low concentration, Aβ1-40
did not induce phosphorylation at Ser262 in either Triton
or SDS soluble fractions in our cell model. This may ex-
plain why we do not see an increase in insoluble tau with
Aβ1-40 treatment (Figure 2).
Aβ1-42 has been shown to induce tau phosphorylation
and the formation of neurofibrillary tangles via a GSK-
3β-dependent mechanism in both in vitro and in vivo
studies [1,19,20]. Aβ42-induced neurotoxicity seems todepend on considerable levels of tau that can be in-
hibited by treatment with GSK-3β inhibitors [21]. The
activity of GSK3β is also regulated positively by the
phosphorylation of Tyr216. Up-regulation of GSK3β ac-
tivity increases phosphorylation of tau at multiple sites
and inhibition of GSK3β specifically decreases the phos-
phorylation of Ser262 [22]. We found that Aβ1-42 acti-
vated GSK3β, but Aβ1-40 did not, which may explain
the different effects of Aβ1-40 and Aβ1-42 on tau phos-
phorylation shown in Figure 3A and C. Our observation
of increased Tau421 in Aβ1-42 treated cells, as well as
previous studies on the correlation between caspase-3
activation and tau cleavage, indicate that the effects we
observed following Aβ1-42 treatment on tau may be me-
diated by caspase-3 activation. In fact, western blot using
a specific antibody to active caspase-3 indicated that
Aβ1-42 activates pro-caspase-3 but no activation was
observed with Aβ1-40 treatment. This may explain the
marked difference we observed between the level of
Tau421 in Aβ1-42 and Aβ1-40 treated cells (Figure 3).
In order to find out how Aβ directly affects the struc-
ture and function of tau in vivo, we used a tau-GFP
Hu et al. Molecular Neurodegeneration 2014, 9:52 Page 9 of 11
http://www.molecularneurodegeneration.com/content/9/1/52transgenic Drosophila model. This is an ideal model be-
cause GFP-tagged tau can be used as a subcellular mar-
ker to study cytoskeletal dynamics in living cells. The
latter avoids potential fixation artifacts and allows for
the dynamic visualization of changes in the structure of
the cytoskeleton. Another advantage of this model is
that low concentrations of Aβ and short incubation
times are sufficient to see the effects of Aβ on tau.
Aβ1-42 injections at concentrations as low as 100pM
caused cytoskeleton disruption in this model, but we
did not see an effect on the cytoskeleton after exposure
to low concentration of Aβ1-40. Interestingly, when we
increased the concentration of Aβ to 10nM, we saw
disrupted cytoskeletal structure in both Aβ1-40 and
Aβ1-42-injected flies. Nonetheless, our data clearly
show marked differential effects of Aβ1-42 and Aβ1-40
on tau function using live cell imaging in this tau trans-
genic fly model.
In vivo studies using a transgenic mouse model ex-
pressing P301S tau were carried out to further assess
how the two main Aβ species may affect tau pathology
in a vertebrate system. In AD, the formation of NFTs
starts in the entorhinal cortex and spreads to the hippo-
campus and eventually to most cortical areas [23]. There
are some advantages of injection of Aβ in the entorhinal
cortex over other brain areas. First, unilateral injections
can be carried out on both the ipsilateral and contra-
lateral entorhinal cortex since there is no cross-talk be-
tween the left and right entorhinal cortex [24] which
allows for a direct comparison of Aβ species in the same
animal. Second, this approach allows us to study how
Aβ and tau interact at the early stage of the disease.
Third, expression of tau in entorhinal cortex can spread
along anatomically connected networks to hippocampus
[25]. Eighteen days after injection, biochemical analyses
with soluble and insoluble fraction from injected brain
tissues demonstrated that Aβ1–42 promotes tau cleav-
age, phosphorylation and aggregation. By contrast, treat-
ment with Aβ1–40 showed no effect on the total tau or
p-tau (recognized by PHF-1) level. Immunostaining with
AT180 showed higher levels of p-tau (Thr231) in the en-
torhinal cortex (injection site), as well as in hippocam-
pus, suggesting that pathological tau induced by Aβ1-42
in the entorhinal cortex may spread to other brain areas
as reported by Gotz and coworkers [1]. The decrease ob-
served in tau phosphorylation at Ser262 in the presence
of Aβ1–40 suggests that Aβ1–40 may inhibit tau path-
ology in old tau transgenic mice that already have tan-
gles. It will worth to try breed BRI-Aβ40 or BRI-Aβ42
mice with tau transgenic mice to see how Aβ1-40 or
Aβ1- 42 affects tau pathogenesis in vivo. Also we are
working on how combination of Aβ 1-40 and Aβ1-42
changes tau pathology compares to Aβ1-42 and study if
Aβ1-40 inhibits tau pathology induced by Aβ1-42.In conclusion, data from cell-based models, tau-GFP
transgenic Drosophila and tau transgenic mouse models
indicate that Aβ1–42 is clearly the pathogenic Aβ species
with respect to inducing the “pathology”; i.e., increased
cleavage, phosphorylation and aggregation of soluble wild-
type tau. By contrast, Aβ1–40 has little to no effect on
the pathogenesis. In fact, Aβ1–40 may even subserve a
protective role in vivo as indicated by the decrease in
phosphorylation at Ser262. Therapeutic strategies that
preferentially target Aβ1–40 thereby increasing the ra-
tio of Aβ1–42 to Aβ1–40 may actually be problematic.
However, targeted Aβ treatments that lower the ratio of
Aβ1–42 to Aβ1–40 may be of therapeutic benefit.
Methods
Aβ Preparation: Aβ1–42 and Aβ1–40
Dry peptide (1 mg) was pretreated with neat trifluoroa-
cetic acid (1 mL), distilled under nitrogen, washed with
1,1,1,3,3,3-hexafluoro-2-propanol (1 mL), distilled under
nitrogen, then dissolved in DMSO to 10 mM, and stored
at −20°C [26].
Cell culture and treatment
C17.2 cells (mouse neural progenitor cell line), a gift from
Marc Diamond, were grown in DMEM, supplemented
with 10% fetal bovine serum, 5% horse serum, and 1%
pen/strep. SH-SY5Ycells (human neuroblastoma cell line)
were cultured in DMEM/F12 medium supplemented with
10% FBS. N2a cells were grown in DMEM/OPTI-MEM
supplemented with 5% FBS.
For transient transfections, cells were plated in 8-well
Lab-Tek chamber slides (Nunc) and were transfected using
Lipofectamine 2000 constructs (Invitrogen) according to
the manufacturer’s recommendations.
For treatment: 200nM Aβ1–42 or Aβ1–40 was added to
the medium and imaged at varied time points thereafter.
Live cell imaging
A Live-cell imaging was performed on a Leica TCS SP5
spectral confocal microscope using an oil-immersion
63× lens. Observation of the cells with 514-nm laser was
performed at low light/laser intensities to prevent photo-
toxicity.
Staining
For Thioflavin-S staining, cells were incubated with 0.025%
Thioflavin-S (in 50% ethanol) for 5 min, rinsed with 50%
ethanol and water, and cover slipped for imaging.
For insoluble tau: Cells fixed with 4% paraformalde-
hyde containing 1% Triton X-100 for 15 min to remove
soluble proteins and fluorescence after extraction was
recognized as insoluble tau. Fluorescence intensity was
quantified with ImageJ.
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For generation of stable tau expressing cell lines, individ-
ual clones of N2a cells were selected in the presence of
500 μg/ml Geneticin after transfection, then picked and
propagated in serum-DME supplemented with 200 μg/ml
Geneticin.
N2a cells stably expressing tau-YFP were treated with
200nM Aβ1–42 or Aβ1–40. 24 h later, cells were col-
lected and cell pellets were resuspended in 1% Triton
lysis buffer and incubated on ice for 15 min. Following
sonication, lysates were centrifuged at 12,000 × rpm for
20 min at 4°C. Supernatants were kept as “Triton frac-
tion,” whereas pellets were resuspended, and sonicated
in 1% SDS lysis buffer. After centrifugation at 12,000 ×
rpm for 20 min at room temperature, supernatants were
saved as “SDS fraction.” Equal proportions of Triton and
SDS fractions were resolved on 4–20% Tris-glycine midi
gel, transferred to nitrocellulose membrane using the
iBlot Dry Blotting System, and probed with specific anti-
bodies in Table 1.
Tau-transgenic fly
UAS-tau-GFP transgenic fly line (tau-GFP is driven by
SPG-specific moody-Gal4 driver) was used for injection
and live imaging. 100 pm or 10nM Aβ1–42 or Aβ1–40
was injected into the body cavity of late embryo (AEL-
21-22 hr), and they were allowed to developed until 3rd
instar larvae (about 4 days). Then the central nerve cord
was dissected out, and mounted in PBS and imaged dir-
ectly. All confocal images were acquired using a Zeiss
LSM 710 system. Stacks of 20–40 0.5 μm confocal sec-
tions were generated. The results for each section were
assembled as a stack.
Stereotaxic injections of Aβ into entorhinal cortex
P301S mice were purchased from Jackson Labs. All ex-
periments were approved by the Institutional Animal
Care and Use Committee at Weill-Cornell Medical Col-
lege. P301S mice (Jackson labs) were anesthetized with iso-
fluorane and placed in a Stoelting stereotaxic instrumentTable 1 Antibodies
Antibody Epitope
HT7 Tau (159-161aa)
pS262 p-Tau (phosphorylated at
AT180 p-Tau (phosphorylated at
PHF-1 p-Tau (phosphorylated at
Tau-C3 Cleaved tau (cleaved at A
Anti-caspase-3 Cleaved caspase-3
Anti-GSK-3β Total GSK3β
Anti-GSK3β (phospho Y216) p-GSK3β (phosphorylated(Stoelting Co., Wood Dale, Illinois) and an incision was
made along the midline. The coordinates for injection
of Aβ42 were determined with reference to the bregma
at position: AP, −3.6 mm; L, ±3.8 mm; DV, −4.5 mm.
Using a 5 μl Hamilton syringe (Hamilton Inc., Bonaduz,
Switzerland) driven by a mini pump (Motorized Stereotaxic
Injector, Stoelting), a total volume of 2 μl of the Aβ1-42,
Aβ1-40 or Saline was injected with an injection speed
of 0.25 μl/min unilaterally into the entorhinal cortex.
The needle was kept in the injection site for 5 min and
then slowly withdrawn to prevent a backflow of the Aβ
preparation.Biochemical analysis for brain extract
Brain tissues were weighed and homogenized in 10 vol-
umes of homogenization buffer (Tris-buffered saline
(TBS), pH 7.4, containing 1× protease and phosphatase
inhibitor mixture with 2 mM EGTA). The homogenized
samples were spun at 21,000 × g for 20 min, the super-
natants were centrifuged at 100,000 × g for 1 h at 4°C to
obtain insoluble pellet and supernatant (S1 fraction).
The insoluble pellet (P1 fraction) was resuspended in
1% sarkosyl in H buffer (10 mM Tris-HCl, 1 mM EGTA,
0.8 M NaCl, 10% sucrose, and protease inhibitor mix-
ture, pH 7.4) and sonicated. The solution was clear and
label as P1, diluted in H2O for ELISA [27]. S1 or P1
fraction was separated on 4–20% Tris-glycine midi gel,
transferred to iblot gel nitrocellulose using the iblot
Dry Blotting System, and probed with HT7, PHF-1,
pS262 and tau-C3.Immunohistochemistry
Brains were placed in 10% buffered formalin, followed
by 30% sucrose. These sections were subsequently stained
using phosphor-tau antibody- AT180. Secondary antibody
was applied, and slides were then incubated with avidin-
biotin complex reagent for 5 min. After rinsing, slides
were treated with the chromogen 3,3′-diaminobenzidine
(Vector Laboratories, SK-4100) to allow visualization.Source
Pierce (cat#MN1000)
Ser262) Invitrogen (cat# 44-750G)
Ser231) Pierce (cat#MN1040)




at Tyr216) Abcam (cat#ab75745)
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